New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MEDI;PFE;CELG;PRXL;ACOR;NPSP;ALKS;AZN;TEVA From The Last 14 Days
Check below for free stories on MEDI;PFE;CELG;PRXL;ACOR;NPSP;ALKS;AZN;TEVA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
September 16, 2014
12:37 EDTAZNNektar reports FDA approval of MOVANTIK for treatment of OIC
Nektar Therapeutics (NKTR) reported that partner AstraZeneca (AZN) announced that the FDA approved MOVANTIK tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist medication for the treatment of opioid-induced constipation, or OIC, in adult patients with chronic, non-cancer pain. In line with the recommendation from the FDA Anesthetic and Analgesic Drug Products Advisory Committee that took place in June, AstraZeneca has agreed to conduct a post-marketing, observational epidemiologic cardiovascular safety study for MOVANTIK. MOVANTIK is expected to be available to patients in the first half of 2015. MOVANTIK is currently a schedule II controlled substance because it is structurally related to noroxymorphone. During the review of the New Drug Application, the FDA evaluated the abuse potential of MOVANTIK and the approved labelling indicates that MOVANTIK has no risk of abuse or dependency. AstraZeneca submitted a petition for the descheduling of MOVANTIK to the U.S. Drug Enforcement Administration, or DEA, in March 2012, which was accepted for review and will be considered by the DEA as part of the process for addressing the descheduling request.
11:51 EDTAZN, PFEOECD looks to close tax loopholes with new proposals
Subscribe for More Information
10:37 EDTNPSPOptions with decreasing implied volatility
Subscribe for More Information
10:19 EDTAZNFDA approves Movantik with requirement for cardiovascular risk study
Subscribe for More Information
08:00 EDTAZNFDA PDUFA Date for Nektar and AstraZeneca''s Movantik is September 16, 2014
07:31 EDTAZNEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:19 EDTPFECompanies' share buybacks at fasttest clip since 2007, WSJ reports
Companies are buying back their own shares at its fastest pace since the financial crisis to fuel a stock rally, reports the Wall Street Journal. According to Birinyi Associates, companies have bought back $338.3B of stock in 1H14, the most since 2007. Citing an analysis by Barclays, companies with the largest buyback programs by dollar value have outperformed the broader market by 20% since 2008. Reference Link
07:02 EDTAZNEli Lilly and AstraZeneca to co-develop and commercialize AZD3293
Subscribe for More Information
06:27 EDTAZNAstraZeneca, Eli Lilly to jointly develop, commercialize AZD3293
AstraZeneca (AZN) and Eli Lilly (LLY) announced an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in development as a potential treatment for Alzheimer's disease. AZD3293 has been shown in Phase I studies to significantly and dose-dependently reduce levels of amyloid beta in the cerebro-spinal fluid of Alzheimer's patients and healthy volunteers. AstraZeneca announced earlier in 2014 its plan to move AZD3293 into registration trials. Under the terms of the agreement, Lilly will pay AstraZeneca up to $500M in development and regulatory milestone payments. AstraZeneca expects to receive the first milestone payment of $50M in the 1H15. The companies will share all future costs equally for the development and commercialization of AZD3293, as well as net global revenues post-launch. AstraZeneca and Lilly aim to progress AZD3293 rapidly into a Phase II/III clinical trial in patients with early Alzheimer's disease. Lilly will lead clinical development, working with researchers from AstraZeneca's Innovative Medicines Unit for neuroscience, while AstraZeneca will be responsible for manufacturing. The companies will take joint responsibility for commercialization of AZD3293. The agreement is subject to customary terms and conditions. It will have no impact on AstraZeneca's 2014 Core Earnings per Share.
September 15, 2014
17:09 EDTNPSPOn The Fly: Closing Wrap
Stocks on Wall Street were mixed to begin the week, as the Dow managed to register mild gains but the Nasdaq was weighed down by slides in a number of so-called "momentum stocks" like Tesla (TSLA). Investors may remain cautious in the next two sessions ahead of the Fed's much anticipated rate decision and accompanying statement, which is due Wednesday. ECONOMIC EVENTS: In the U.S., New York Fed's Empire state survey for September rose to a five-year high of 27.54. Industrial production unexpectedly dipped 0.1% in August from a downwardly revised 0.2% July gain, missing the forecast for a rise of 0.3%. Capacity utilization dropped to 78.8% last month from 79.1% previously. In China, industrial output increased 6.9% in August versus the same period a year earlier, which was its weakest advance, excluding months that fell during New Year holidays, since December 2008. Chinese retail sales growth for August came in at 11.9%, missing the consensus estimate. COMPANY NEWS: Shares of Apple (AAPL) edged down 3c, or 0.03%, to $101.63 despite the company's announcement that a record 4M iPhone 6 and iPhone 6 Plus pre-orders were placed in the first 24 hours that ordering was available. Demand for the new phones exceeds the initial pre-order supply, the company added, stating that delivery of "many" iPhone pre-orders have been pushed out to October... Microsoft (MSFT) slid 45c, or 0.97%, to $46.24 after the company confirmed an agreement to acquire Mojang, the developer for the "Minecraft" video game franchise, for $2.5B... MAJOR MOVERS: Among the notable gainers was Avanir Pharmaceuticals (AVNR), which surged $5.75, or 85.31%, to $12.49 and was upgraded to Buy from Hold at Jefferies after the company announced results from its phase II clinical trial evaluating the safety and efficacy of its treatment of agitation in patients with Alzheimer's disease. Also higher was SABMiller (SBMRY), which jumped $4.72, or 8.5%, to $60.26 after the Wall Street Journal said that ABInBev (BUD) was looking to obtain financing for an acquisition of the U.K.-based brewer and Heineken (HEINY) confirmed that it rebuffed SABMiller's approach regarding a potential transaction. The news of potential consolidation in the space also drove other beer makers highers, with Molson Coors (TAP) rising $4.20, or 5.85%, to $76.00 and Boston Beer (SAM) gaining 71c, or 0.33%, to $218.47. Among the noteworthy losers was Tesla (TSLA), which dropped $25.34, or 9.08%, to $253.86 after Morgan Stanley analyst Adam Jones wrote that he agrees with the assertion of Tesla's CEO Elon Musk that the company's stock may have gotten ahead of itself. Also lower were shares of NPS Pharmaceuticals (NPSP), which fell $5.42, or 16.56%, to $27.28 after Oppennheimer and Jefferies stated that approval of its Natpara drug for hypoparathyroidism could be delayed after concerns were raised during an FDA panel meeting, even though the advisors were in favor of approving the drug. INDEXES: The Dow rose 43.63, or 0.26%, to 17,031.14, the Nasdaq dropped 48.70, or 1.07%, to 4,518.90, and the S&P 500 declined 1.41, or 0.07%, to 1,984.13.
12:31 EDTNPSPOn The Fly: Midday Wrap
Subscribe for More Information
09:25 EDTPFEJPMorgan biotech analysts hold an analyst/industry conference call
Analysts assess Pfizer's M&A options on an Analyst/Industry conference call to be held on September 15 at 10 am.
09:16 EDTNPSPOn The Fly: Pre-market Movers
Subscribe for More Information
08:05 EDTNPSPNPS Pharmaceuticals expected to win Natpara approval at Leerink
Subscribe for More Information
07:55 EDTALKSAlkermes shares attractive ahead of Q1 catalysts, says Leerink
Leerink says its recent meeting with Alkermes management confirmed its conviction that the company is executing on its growth strategy. Leerink believes clinical trials for ALKS 8700 in multiple sclerosis, ALKS 7106 in abuse deterrent opiate analgesic and the Phase II trial for ALKS 3831 in schizophrenia are all billion dollar market opportunities that are not reflected in the current stock price. The firm finds the stock attractively valued ahead of clinical data readouts that start in early Q1 of 2015. It reiterates an Outperform rating on Alkermes with a $66 price target.
07:51 EDTNPSPNPS Pharmaceuticals PDUFA could be delayed, says Oppenheimer
After NPS Pharmaceuticals' stock rallied 25% on briefing materials that were thought to be benign and an FDA panel voted 8-5 to recommend approval of the company's Natpara drug, Oppenheimer thinks the PDUFA date for Natpara, could be delayed. The firm also believes that the panel's commentary was not "an overwhelming victory" for the drug, but Oppenheimer predicts that it will eventually be approved and keeps a $40 price target and Outperform rating on the name.
07:45 EDTNPSPNPS Pharmaceuticals approval likely to be delayed, says Jefferies
Subscribe for More Information
07:27 EDTPFE, CELGIBC Life Sciences to hold a conference
Subscribe for More Information
07:27 EDTAZN, PFEPfizer acquisition could drive shares higher, says JPMorgan
Subscribe for More Information
September 14, 2014
13:32 EDTPFEPfizer shares look cheap, Barron's says
Subscribe for More Information
September 12, 2014
17:09 EDTNPSPFDA recommends approval of NPS Pharmaceuticals Natpara for Hypoparathyroidism
Subscribe for More Information
10:32 EDTPFE, AZNPfizer CEO says company still open to inversion deal, FT says
Pfizer (PFE) CEO Ian Read said U.S. rhetoric against tax inversions has been "political theater" ahead of midterm elections and made clear that his company is still open to a potential tax-saving acquisition, according to Financial Times, which added Read's comment about not being “held hostage” over price would likely be read as a signal the company might look elsewhere after being rebuffed by AstraZeneca (AZN). The Fly notes that Bloomberg previously reported, citing people familiar with the matter, that Pfizer is looking at targets other than AstraZeneca, including Actavis (ACT). Shares of Actavis trading in New York are up 2% this morning. Reference Link
09:01 EDTTEVATeva to present Copaxone gene expression analysis
Subscribe for More Information
08:06 EDTTEVATeva presents new clinical safety data in RRMS patients treated with Laquinimod
Teva (TEVA) and Active Biotech (ACTI) announced new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis, or RRMS, who were treated with laquinimod in Phase II, Phase III and open-label extension studies for two or more years. The pooled safety analysis of the Phase II LAQ/5063 and the Phase III ALLEGRO and BRAVO extension studies supports findings observed in the core studies where currently identified risks were observed within the first months of laquinimod treatment. In the pooled safety analysis, rates of adverse events, or AEs, and serious AEs were lower in the open-label extensions than in the core studies and less than three percent of patients discontinued treatment due to AEs during these extensions. Additionally, shifts to potentially significant laboratory values were considerably lower in patients exposed to at least two years of laquinimod.
08:03 EDTTEVATeva, Active Biotech present laquinimod follow-up data
Subscribe for More Information
07:47 EDTNPSPNPS Pharmaceuticals to host conference call
Subscribe for More Information
07:17 EDTNPSPFDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting
The Committee discusses NPSP Pharmaceuticals' Biologics License Application (BLA) 125511, proposed trade name, NATPARA, (established name: Recombinant Human Parathyroid Hormone (rDNA) or (rhPTH), for the proposed indication of replacement for parathyroid hormone (1-84) for the long-term treatment of hypoparathyroidism will be held in Hyattsville, Maryland on September 12 at 8 am. Webcast Link
07:09 EDTNPSPNPS Pharma stock trading halted, FDA to review Natpara BLA
Subscribe for More Information
07:00 EDTNPSPNPS Pharmaceuticals trading halted, pending news
Subscribe for More Information
September 11, 2014
11:07 EDTNPSPOptions with decreasing implied volatility
Subscribe for More Information
09:31 EDTTEVATeva announces new data from Phase IIIb GLACIER study
Subscribe for More Information
06:02 EDTNPSPNPS could trade to high $30s on positive vote, says Leerink
Leerink believes an FDA advisory committee tomorrow will vote in favor of NPS Pharmaceuticals' Natpara as a chronic treatment for hypoparathyroidism. It says shares could trade in the mid-to-high $30s on a positive vote with further upside on FDA approval by October 24. The firm reiterates an Outperform rating on NPS Pharmaceuticals with a $40 price target.
03:27 EDTTEVATeva Canada announces launch of generic version of Cipralex
Subscribe for More Information
September 10, 2014
16:19 EDTNPSPOn The Fly: Closing Wrap
Subscribe for More Information
15:21 EDTAZNAstraZeneca has a conference call hosted by JPMorgan
Subscribe for More Information
14:25 EDTTEVATeva Canada announces launch of generic version of Cipralex
Subscribe for More Information
13:03 EDTNPSPOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday, with the Nasdaq comfortably the leader among the major averages. The market opened relatively quietly as investors digested the bevy of research reports surrounding apple (AAPL) and the companies effected by its new products and services announced yesterday. The averages crossed into negative ground early in trading, made it back to positive territory just before the lunch hour, and now are all in the black. ECONOMIC EVENTS: In the U.S., wholesale inventories rose 0.1% in July, which was below expectations for an increase of 0.5%. Wholesale sales rose 0.7%, which was above the 0.6% increase that was forecast. COMPANY NEWS: The strength in the Nasdaq was largely attributable to Apple, which rose about 2.5% the day after unveiling two new, larger iPhone 6 models, the Apple Watch and a new payment system, named Apple Pay... Dollar General (DG) "went hostile" in its pursuit of peer Family Dollar (FDO), commencing a tender offer to acquire all of the company's outstanding shares for $80.00 per share in cash. Family Dollar confirmed the unsolicited offer, noting that the terms are the same as those in the previously rejected proposal made by Dollar General on September 2. Family Dollar said its board will review and consider Dollar General’s tender offer, but added that the board has not changed its recommendation in support of the company's merger with Dollar Tree (DLTR). MAJOR MOVERS: Among the notable gainers was NPS Pharmaceuticals (NPSP), which rose 21% after several analysts said FDA briefing documents for an advisory panel meeting on its Natpara drug were more favorable than expected. Also higher was clothing and accessories retailer Land's End (LE), which gained nearly 17% after the company's second quarter results beat the estimate of the only analyst that covers it. Among the noteworthy losers was eBay (EBAY), which fell for a second straight day after Apple announced its new mobile payment system, Apple Pay, that could come in direct competition with eBay's PayPal service. Shares of PayPal's parent were downgraded to Neutral this morning at Piper Jaffray and fell 3% near noon. Also lower following yesterday's presentation by Apple was partner GT Advanced (GTAT), which was downgraded at Goldman, Piper Jaffray and Dougherty and dropped more than 14% after it was revealed that sapphire will be used in the display cover of Apple Watch but not the iPhone 6. INDEXES: Near midday, the Dow was up 16.02, or 0.09%, to 17,029.89, the Nasdaq was up 21.10, or 0.46%, to 4,573.38, and the S&P 500 was up 2.62, or 0.13%, to 1,991.06.
11:48 EDTNPSPStocks with call strike movement; GTAT NPSP
GT Advanced (GTAT) March 15 call option implied volatility decreased 6% to 39, NPS Pharmaceuticals (NPSP) January 35 call option implied volatility decreased 17% to 60 according to IVolatility.
11:11 EDTNPSPNPS Pharmaceuticals management to meet with Needham
Meetings to be held in Chicago on September 16 and in Kansas City/Minneapolis on September 17 hosted by Needham.
10:51 EDTNPSPNPS briefing docs more favorable than expected, says FBR Capital
Subscribe for More Information
10:48 EDTNPSPNPS briefing docs 'much less negative' than feared, says Leerink
Subscribe for More Information
10:36 EDTNPSPNPS Pharmaceuticals briefing docs for Naptara benign, says Canaccord
Subscribe for More Information
08:27 EDTNPSPNPS Pharmaceuticals rises after FDA briefing materials posted
Subscribe for More Information
08:06 EDTNPSPNPS says FDA posts briefing materials for meeting reviewing Natpara
Subscribe for More Information
September 9, 2014
15:13 EDTNPSPNPS Pharmaceuticals September volatility elevated into PDUFA
Subscribe for More Information
08:17 EDTNPSPNPS Pharmaceuticals likely volatile on briefing docs, says FBR Capital
Subscribe for More Information
07:51 EDTCELGNICE says Abraxane price not justified by limited benefit in pancreatic cancer
Subscribe for More Information
06:51 EDTALKSAlkermes management to meet with Leerink
Subscribe for More Information
September 8, 2014
14:37 EDTNPSPNPS Pharmaceuticals September volatility elevated into PDUFA
Subscribe for More Information
14:13 EDTAZNConnecticut AG tells FDA to speed up generic Nexium
A news release from the Connecticut Attorney General George Jepsen, dated September 4, says: In comments to a Citizen Petition filed with the FDA, Attorney General George Jepsen called on the federal agency to expeditiously end several years of delays preventing the sale of a generic form of the drug esomeprazole magnesium , esomeprazole, currently marketed under the brand name Nexium. Nexium is the second highest-selling pharmaceutical drug in the United States, and delays in approving generic versions have cost consumers and government healthcare payers billions of dollars. In his comments, Attorney General Jepsen alleges that an agreement between drug manufacturers Ranbaxy (RBXLY) and AstraZeneca Pharmaceuticals (AZN), Nexium’s brand-name manufacturer, has prevented other drug-makers from launching a generic version of the drug, ultimately harming all consumers by artificially inflating prices. Ranbaxy was first-to-file with the FDA for approval of a generic form of Nexium. AstraZeneca sued Ranbaxy for patent infringement, and the dispute was settled by an agreement that provided financial incentives for Ranbaxy to delay entry of its generic into the consumer market. Reference Link
12:40 EDTTEVAFTC sues AbbVie over blocking of AndroGel generics
The Federal Trade Commission has filed a complaint in federal district court charging several pharmaceutical companies with "illegally blocking American consumers’ access to lower-cost versions of the blockbuster drug AndroGel." The FTC's complaint alleges that AbbVie (ABBV) and its partner Besins Healthcare filed baseless patent infringement lawsuits against potential generic competitors to delay the introduction of lower-priced versions of the testosterone replacement drug AndroGel. While the lawsuits were pending, AbbVie then entered into an anticompetitive pay-for-delay settlement agreement with Teva Pharmaceuticals (TEVA) to further delay generic drug competition, the FTC claims. Reference Link
11:05 EDTNPSPOptions with increasing implied volatility
Options with increasing implied volatility: NPSP GILD VNET AVNR GTAT YHOO RHT VRTX SDRL COV MYL
09:27 EDTTEVALeerink biotech analyst holds a luncheon meeting with a conference call
Biotech Analyst Schwartz provides an update on key trends and controversies for marketed MS therapies and discusses new data presented at ACTRIMS-ECTRIMS at a Luncheon Meeting with an Analyst/Industry conference call to be held in Boston on September 11 at 12:15 pm.
08:02 EDTTEVATeva completes Reslizumab Phase III program
Subscribe for More Information
07:26 EDTCELGMorgan Stanley to hold a conference
Subscribe for More Information
07:15 EDTMEDI, PFEIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
07:02 EDTAZNAstraZeneca announces availability of Bydureon pen 2mg
Subscribe for More Information
September 5, 2014
11:47 EDTNPSPOptions with increasing implied volatility
Subscribe for More Information
10:32 EDTNPSPNPS Pharmaceuticals September volatility increases into PDUFA
Subscribe for More Information
10:05 EDTTEVA, CELGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Actavis (ACT) initiated with a Buy at ISI Group... Akamai (AKAM) initiated with a Buy at UBS... Alexion (ALXN) initiated with a Buy at SunTrust... Allegion (ALLE) initiated with a Buy at Buckingham... Allergan (AGN) initiated with a Buy at ISI Group... Aviat Networks (AVNW) initiated with a Neutral at H.C. Wainwright... Celgene (CELG) initiated with a Buy at SunTrust... EZCORP (EZPW) initiated with a Hold at Jefferies... Eaton (ETN) initiated with a Neutral at Buckingham... Emerson (EMR) initiated with a Neutral at Buckingham... HMS Holdings (HMSY) initiated with an Overweight at Stephens... Incyte (INCY) initiated with a Buy at SunTrust... Ingersoll-Rand (IR) initiated with a Neutral at Buckingham... Insmed (INSM) initiated with an Outperform at Cowen... Intercept (ICPT) initiated with an Outperform at Cowen... Johnson & Johnson (JNJ) initiated with an Outperform at BMO Capital... Lennox (LII) initiated with a Neutral at Buckingham... Mylan (MYL) initiated with a Hold at ISI Group... Orion Engineered Carbons (OEC) initiated with a Buy at Goldman... Parker-Hannifin (PH) initiated with a Buy at Buckingham... Pentair (PNR) initiated with a Neutral at Buckingham... Pharmacyclics (PCYC) initiated with a Neutral at SunTrust... Rockwell Automation (ROK) initiated with a Neutral at Buckingham... Sabre (SABR) initiated with an Outperform at Oppenheimer... Santander Consumer (SC) initiated with a Buy at Jefferies... Springleaf (LEAF) initiated with a Buy at Jefferies... Susser Petroleum (SUSP) initiated with a Neutral at Credit Suisse... Teva (TEVA) initiated with a Buy at ISI Group... Valeant (VRX) initiated with a Buy at ISI Group... WESCO (WCC) initiated with a Neutral at Buckingham... Watsco (WSO) initiated with a Neutral at Buckingham... Weyerhaeuser (WY) initiated with a Neutral at JPMorgan... World Acceptance (WRLD) initiated with a Hold at Jefferies.
September 4, 2014
17:56 EDTCELGCelgene initiated with a Buy at SunTrust
Target $121.
17:16 EDTTEVATeva initiated with a Buy at ISI Group
Subscribe for More Information
17:15 EDTAZNAstraZeneca granted orphan status for EFGR non-small cell lung cancer treatment
The FDA posted on its website that AstraZeneca has been granted orphan status for its treatment of epidermal growth factor receptor, or EFGR, mutation-positive non-small cell lung cancer. Reference Link
16:05 EDTPFEPfizer granted orphan status for sickle cell disease drug
Subscribe for More Information
10:45 EDTNPSPNPS drops after Feuerstein tweets about interview offer
Subscribe for More Information
10:06 EDTNPSPNPS Pharmaceuticals September volatility elevated into PDUFA
NPS Pharmaceuticals September call option implied volatility is at 96, October is at 71, November is at 68; compared to its 26-week average of 64 according to Track Data, suggesting large near term price movement into PDUFA for Natpara on September 12.
08:02 EDTTEVATeva launches generic Baraclude in U.S.
Teva (TEVA) announces the launch of the generic equivalent to Baraclude tablets in the U.S. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Baraclude is marketed by Bristol-Myers Squibb (BMY).
07:33 EDTCELGCelgene announces REVLIMID Phase III FIRST trial met primary endpoint
Subscribe for More Information
07:23 EDTPFE, AZNAstraZeneca called for inversion clamp down as part of defense, WSJ says
Amid its defense against an unsolicited takeover bid from rival Pfizer (PFE), AstraZeneca (AZN) hired advisers with close ties to the Obama administration, who made calls to senior administration officials urging a clamp down on tax inversions, said The Wall Street Journal, citing people familiar with the previously undisclosed calls. Reference Link
07:21 EDTTEVAMedidata can obtain major new platform customers, says Stifel
Noting that Medidata (MDSO) partners with Veeva, Stifel believes that a number of Veeva (VEEV) customers could become Medidata platform customers, especially if they already use Medidata for R&D and clinical trial solutions. The firm identifies Merck (MRK), Gilead (GILD), and Teva (TEVA) as companies that may become platform clients for Medidata. Stifel keeps a $55 price target and Buy rating on Medidata.
September 3, 2014
11:30 EDTPFEPfizer has conference call hosted by Bernstein
Subscribe for More Information
10:46 EDTPRXLHigh option volume stocks
Subscribe for More Information
07:05 EDTALKSAlkermes completes patient enrollment in Phase 2 ALKS 3831 study
Subscribe for More Information
05:44 EDTTEVA, AZNTeva announces positive judgement in patent case against AstraZeneca
Subscribe for More Information
September 2, 2014
09:41 EDTCELGActive equity options trading on open
Subscribe for More Information
08:19 EDTCELGCelgene GED301 drug has positive risk/reward ratio in near-term, says Bernstein
Bernstein believes that the upcoming trial of Celgene's GED0301 drug for Crohn's disease has very little risk in the near-term, while the presentation of results of a study of the drug next month should be positive for the stock. The firm thinks that the drug could emerge as a popular combination partner for other systemic drugs in patients who continue to have disease symptoms. Bernstein is more cautious about the drug's outlook starting in 2016 but keeps a $103 price target and Outperform rating on the stock.
08:02 EDTTEVATeva reports statistically significant results in reslizumab trial
Teva Pharmaceutical Industries announced that reslizumab, an investigational anti-IL-5 monoclonal antibody, demonstrated clear levels of efficacy in achieving the primary endpoint of reduction in the frequency of clinical asthma exacerbations compared to placebo in two pivotal Phase III studies in patients with inadequately controlled moderate to severe asthma with elevated levels of blood eosinophils. In both trials, reslizumab treatment showed both clinically relevant and statistically significant reductions in the frequency of CAE compared to placebo. Reslizumab has also demonstrated a positive effect on lung function and asthma control in the Phase III program . The combination of an effect on clinically important exacerbations and on improvements and preservation of lung function suggest that reslizumab may be a uniquely differentiated treatment for patients with moderate to severe asthma with elevated levels of blood eosinophils. This initial set of results shows the adverse event profile of reslizumab was comparable to placebo in both trials. The incidence of common AEs was consistent with those seen in a moderate to severe asthma population, the most frequent being upper respiratory tract infections, asthma and headache. Further analyses of additional efficacy and safety data are ongoing. These new data are from two global Phase III 12-month, randomized, double-blind, placebo-controlled, parallel-group studies, evaluating the efficacy and safety of intravenously administered reslizumab once every four weeks, compared to placebo in asthma patients that are inadequately controlled by standard of care therapy.
07:12 EDTALKSCredit Suisse names its Top U.S. Pharmaceutical picks for 2H
Subscribe for More Information
06:45 EDTAZNAstraZeneca volatility elevated
Subscribe for More Information
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use